HURA

ANALYST NOTE: HURA (TuHURA Biosciences, Inc.) Date: 2026-06-12 Current Price: $1.88

1. Structural Readiness

State: Forming Aggressive/Pre-Breakout Entry: $1.88 (Current Price). Breakout Level: $2.15 (Structural resistance level required to confirm the coil). Extension: N/A (Price is within the consolidation range, not extended above the breakout level). ATR Context: Current ATR is 11.6% (Extreme). This indicates high volatility and significant risk of whipsaw during the formation phase. Historically, extreme ATR readings in forming coils suggest a higher probability of a failed breakout or a sharp, violent move in either direction. Pivot Strength: Weak (Price is currently testing the lower bound of the consolidation range).

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis: None named at this date. Analysis: This is not a macro-driven or secular-theme play. The investment case is strictly dependent on the quality of the technical setup (the coil formation) and the binary nature of the company's clinical milestones. There is no broad market tailwind or secular growth narrative attached to this specific ticker as of June 2026. The conviction must be derived entirely from the structural integrity of the price action and the specific business fundamentals of the IFx-2.0 and TBS-2025 programs.

3. Business Fundamentals

Company Overview: TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapeutics to overcome resistance to cancer immunotherapies. Core Assets & Pipeline:

• IFx-2.0: An innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. As of June 2025, the company initiated a single randomized placebo-controlled Phase 3 registration trial for IFx-2.0 as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced/metastatic Merkel cell carcinoma (MCC). The company anticipates topline results from this accelerated approval trial in the second half of 2027. Enrollment is expected to take 18–24 months from initiation.
• TBS-2025: Acquired via the Kineta, Inc. merger on June 30, 2025. This is a novel VISTA-inhibiting monoclonal antibody. Following the acquisition, the company plans to investigate TBS-2025 in a randomized Phase 2 trial in combination with a menin inhibitor versus menin inhibitor alone in mutated NPM1 (mut NPM1) Acute Myeloid Leukemia (AML).
• Strategic Context: The company is targeting unmet medical needs, specifically in AML where patients failing menin inhibitors have no approved effective therapies.

Financial Position & Liquidity:

• Capital Resources: As of the March 31, 2026 filing, the company expects existing capital resources, including future proceeds from a revolving line of credit, to fund operations through the end of 2028.
• Credit Facility: On April 21, 2026, the company entered into a Loan Agreement with Parkview Holdings One LLC (an affiliate of K&V Investment LLC, a >5% holder) for a $50 million revolving credit facility maturing on April 21, 2031.
• Management Expectations: Management expects to discuss development plans with the FDA late in the first half of 2026 and initiate the planned Phase 1b/2 trial (likely for TBS-2025 or a new indication) as early as the second half of 2026.

4. Archetype and Conviction

Archetype: Deep Value Recovery / Clinical Catalyst Speculator Fit: The company fits the "Deep Value Recovery" archetype in the sense that it is trading at a low absolute price ($1.88) with a significant cash runway extension ($50M credit line) and a clear path to a major binary event (Phase 3 topline in H2 2027). However, it lacks the "Quality Compounder" traits of a commercial-stage firm. It is a binary event-driven name where the "value" is the probability of a successful Phase 3 readout.

Conviction Stack:

• Thesis Strength: Low (No secular thesis; purely tactical).
• Evidence Quality: High (Strong primary filings from May 2026 and March 2026 detailing specific trial designs, timelines, and capital structure).
• Structural Quality: Moderate. The "Forming" coil suggests a base is being built, but the Extreme ATR (11.6%) is a significant negative signal. High volatility often precedes a breakdown in speculative biotech names unless a catalyst is imminent.
• Rerating Potential: High, but binary. A successful Phase 3 readout in 2027 could drive a massive rerating, but a failure would likely result in a collapse.

Valuation Context: The $50M credit facility provides a specific floor for liquidity, reducing near-term dilution risk compared to names without such backing. However, the stock price of $1.88 suggests the market is pricing in significant execution risk or a low probability of success for the Phase 3 trial.

5. Invalidations and Gaps

Invalidation Triggers:

• Fundamental: Any delay in the FDA discussion scheduled for "late first half of 2026" or a negative update on the Phase 3 enrollment progress for IFx-2.0.
• Capital: If the company draws down the credit facility unexpectedly or announces a new equity raise before the 2028 runway is exhausted.

Evidence Gaps:

• Phase 1b/2 Data: While the company plans to initiate a Phase 1b/2 trial in H2 2026, no data from this trial exists as of June 2026. The success of the Phase 3 program relies on the safety/efficacy profile established in earlier stages, which is not yet public for the specific TBS-2025 combination.
• Market Size Quantification: The filings mention the unmet need in AML (30-35% of cases) but do not provide specific TAM/SAM/SOM calculations for the TBS-2025 program.
• Competitive Landscape: No specific data on competing menin inhibitors or VISTA inhibitors in the pipeline is provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: $50M revolving credit facility secured from Parkview Holdings maturing in 2031; Phase 3 trial for IFx-2.0 initiated in June 2025 with topline data expected H2 2027; acquisition of TBS-2025 via Kineta merger expands pipeline into AML. Key risks: Extreme ATR of 11.6% indicates high volatility and potential for sharp downside; binary nature of Phase 3 results creates all-or-nothing outcome; no named secular thesis to support valuation multiple expansion; potential for FDA delays in planned H1 2026 discussions. Sizing hint: Position size should be minimal (e.g., <1% of portfolio) due to extreme volatility and binary risk profile; treat as a lottery ticket on the Phase 3 outcome rather than a core holding. Expected path: Price likely to remain in consolidation range ($1.65-$2.15) while awaiting FDA feedback in H1 2026 and Phase 3 enrollment progress; potential for a sharp breakout if FDA feedback is positive or a breakdown if enrollment stalls. Expected horizon: 12 to 18 months (until FDA discussion results or Phase 3 enrollment milestones).